Clinical Trial Results:
Phase II, Randomised, Double-Blind, Cross-over Study to Compare the
24-hour FEV1-time Profile of Orally Inhaled Olodaterol, delivered with
the Respimat® Inhaler, after 3 Weeks of Olodaterol Once Daily 5 μg [2
actuations of 2.5 μg], Twice Daily 2.5 μg [2 actuations of 1.25 μg] and
Placebo or after 3 Weeks of Once Daily 10 μg [2 actuations of 5 μg],
Twice Daily 5 μg [2 actuations of 2.5 μg] and Placebo Administration
in Patients with Moderate to Severe Persistent Asthma
Summary
|
|
EudraCT number |
2008-006625-14 |
Trial protocol |
DE HU SI AT |
Global completion date |
19 Dec 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 May 2016
|
First version publication date |
05 Apr 2015
|
Other versions |
|
Summary report(s) |
1222.29 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.